Clinical Trial Update: Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated adding the IGF-1R inhibitor cixutumumab to standard androgen deprivation therapy with or without bicalutamide in newly diagnosed metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Casodex (bicalutamide)
• Cixutumumab (Cixutumumab)
• Lupron (leuprolide)
• Zoladex (goserelin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Adenocarcinoma, Recurrent Prostate Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-10-06